We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety and Effectiveness Study of PRK Using the ALLEGRETTO WAVE® EYE-Q Excimer Laser System

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01699087
First Posted: October 3, 2012
Last Update Posted: April 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Alcon Research
  Purpose
The purpose of this study is to evaluate the safety and effectiveness of the ALLEGRETTO WAVE EYE-Q excimer laser system for the reduction of myopia with or without astigmatism in subjects undergoing photorefractive keratectomy (PRK) treatment.

Condition Intervention
Myopia Astigmatism Procedure: Photorefractive keratectomy (PRK) Device: ALLEGRETTO WAVE EYE-Q excimer laser system

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Safety and Effectiveness Study of PRK for Myopia With or Without Astigmatism Using the ALLEGRETTO WAVE® EYE-Q Excimer Laser System

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Percentage of Eyes Achieving Uncorrected Visual Acuity (UCVA) of 20/40 or Better at Refractive Stability in Eyes With Best Spectacle-corrected Visual Acuity (BSCVA) of 20/20 or Better Preoperatively [ Time Frame: Month 6 (post second eye surgery) ]
    Visual acuity, with and without correction, was assessed monocularly using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at 4 meters under photopic conditions . The with-correction assessment was made with the manifest refraction at 4 meters.

  • Percentage of Eyes Achieving Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.0 D of Zero at Refractive Stability [ Time Frame: Month 6 (post second eye surgery) ]
    Manifest refraction spherical equivalent (MRSE) is calculated as follows: sphere + 1/2 cylinder. The sphere and cylinder values are from the manifest refraction assessment. The manifest refraction assessment was conducted monocularly with the ETDRS chart at 4 meters under photopic conditions using a phoropter.

  • Percentage of Eyes Achieving MRSE Within ± 0.5 D of Zero at Refractive Stability [ Time Frame: Month 6 (post second eye surgery) ]
    Manifest refraction spherical equivalent (MRSE) is calculated as follows: sphere + 1/2 cylinder. The sphere and cylinder values are from the manifest refraction assessment. The manifest refraction assessment was conducted monocularly with the ETDRS chart at 4 meters under photopic conditions using a phoropter.

  • Percentage of Eyes Achieving Manifest Refractive Cylinder Within ± 1.0 D of Zero at Refractive Stability [ Time Frame: Month 6 (post second eye surgery) ]
    Manifest refraction was performed monocularly under photopic lighting conditions using an ETDRS chart at 4 meters. The subject was manually refracted to his/her best correction using a phoropter.

  • Percentage of Eyes Achieving Manifest Refractive Cylinder Within ± 0.5 D of Zero at Refractive Stability [ Time Frame: Month 6 (post second eye surgery) ]
    Manifest refraction was performed monocularly under photopic lighting conditions using an ETDRS chart at 4 meters. The subject was manually refracted to his/her best correction using a phoropter.

  • Percentage of Eyes That Have a Change of ≤ 1.0 D in MRSE and Manifest Refractive Cylinder Between Consecutive Scheduled Visits [ Time Frame: Up to Month 24 (post second eye surgery) ]
    MRSE is calculated as sphere + 1/2 cylinder. The sphere and cylinder values are from the manifest refraction assessment. The manifest refraction assessment was conducted monocularly with the ETDRS chart at 4 meters under photopic conditions using a phoropter.

  • Cumulative Incidence of Ocular Serious Adverse Events by Eye [ Time Frame: Up to Month 24 (post second eye surgery) ]
    Participants were followed for the duration of the study, an expected average of 24 months.

  • Percentage of Eyes With BSCVA Decrease of ≥ 2 Lines From Baseline at Refractive Stability [ Time Frame: Month 6 (post second eye surgery) ]
    Visual acuity with correction was assessed monocularly using the ETDRS chart at 4 meters under photopic conditions . A decrease in 2 lines or more is considered clinically relevant (i.e. worse).

  • Percentage of Eyes With a BSCVA Worse Than 20/40 (for Eyes With BSCVA of 20/20 or Better Preoperatively) at Refractive Stability [ Time Frame: Month 6 (post second eye surgery) ]
    Visual acuity with correction was assessed monocularly using the ETDRS chart at 4 meters under photopic conditions .

  • Percentage of Eyes With > 2.0 D of Induced Manifest Refractive Cylinder Magnitude, as Compared to Baseline, at Refractive Stability [ Time Frame: Month 6 (post second eye surgery) ]
    Manifest refraction was performed monocularly under photopic lighting conditions using an ETDRS chart at 4 meters. The subject was manually refracted to his/her best correction using a phoropter. The cylinder value is from the manifest refraction assessment. The induced manifest refractive cylinder is the change in magnitude of cylinder compared to baseline.


Enrollment: 176
Study Start Date: August 2012
Study Completion Date: July 2015
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PRK ALLEGRETTO
Photorefractive keratectomy (PRK) surgery using the ALLEGRETTO WAVE EYE-Q excimer laser system for myopic wavefront-optimized ablation
Procedure: Photorefractive keratectomy (PRK)
In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.
Device: ALLEGRETTO WAVE EYE-Q excimer laser system
The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery
Other Names:
  • ALLEGRETTO WAVE Eye-Q
  • WaveLight® EX500
  • WaveNet™ Planning Software
  • ALLEGRETTO WAVE® EYE-Q excimer laser system (Model 1010-3)

Detailed Description:

This was a prospective, multi-center, single group study. Subjects underwent bilateral PRK in which the second eye was treated no sooner than 1 week and no later than 30 days after the first eye's PRK treatment. Subjects were followed for 2 years after surgery.

The protocol underwent 4 amendments. The key differences between the protocol versions were clarifications of the planned analyses and adverse event reporting procedures. There were no changes in the inclusion and exclusion criteria or non-adverse event related study assessments between the protocol versions 1-5.

Refractive stability of manifest refraction spherical equivalent (MRSE) and manifest refractive cylinder was defined as established when:

  • At least 95% of the treated eyes had a change ≤ 1.0 diopter between manifest refractions performed at any 2 manifest refractions at least 3 months apart
  • The mean rate of change, as determined by a paired analysis, was ≤ 0.5 diopter per year (0.04 D/month) over the same time period
  • The mean rate of change decreased monotonically over time, with a projected asymptote of zero or a rate of change attributable to normal aging
  • The 95% confidence interval for the mean rate of change included zero or a rate of change attributable to normal aging.

Refractive stability was assessed for pairs of visits within an interval and was defined to occur at the latter time point of the first interval at which stability was achieved.

In the final amendment to the protocol, 3 secondary objectives were made co-primary in response to Agency comments. All endpoints and analyses were modified to match.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects desiring refractive correction of myopia up to -6.00 Diopter (D) sphere with or without astigmatism 0 to -3.00 D and up to -6.00 D manifest refraction spherical equivalent (MRSE) at the spectacle plane measured by manifest refraction;
  • Minimum best spectacle corrected visual acuity (BSCVA) in the treated eye of 20/25;
  • Uncorrected visual acuity (UCVA) 20/40 or worse in the treated eye;
  • Less than 0.75 D spherical equivalent (SE) difference between cycloplegic and manifest refractions;
  • Stable refraction (within ± 0.5 D), as determined by MRSE for a minimum of 12 months prior to surgery;
  • Demonstrated stable refraction for contact lens wearers, as specified in protocol;
  • Signed informed consent document;
  • Willing and able to comply with schedule for follow-up visits;
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Females who are pregnant, lactating, or planning a pregnancy during the time course of the study, or have another condition associated with the fluctuation of hormones that could lead to refractive changes;
  • Participation in other clinical trials during this study;
  • Acute or chronic disease or illness that would increase the operative risk or confound the outcomes of the study;
  • Dry eye syndrome as determined by the short questionnaire for dry eye syndrome;
  • Systemic medications that may confound the outcome of the study or increase the risk to the subject by affecting wound healing or tissue repair, including, but not limited to steroids, antimetabolites, immune response modifying drugs, etc.;
  • Nystagmus or any other condition that would prevent a steady gaze during the PRK treatment or other diagnostic tests;
  • Ocular condition that may predispose the subject to future complications;
  • Previous intraocular or corneal surgery;
  • Subjects who desire to have monovision;
  • A known sensitivity to medications used for study procedures, including PRK;
  • Presence or history of any condition or finding that makes the subject unsuitable as a candidate for PRK or study participation or may confound the outcome of the study, in the opinion of the Investigator;
  • Other protocol-defined exclusion criteria may apply.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01699087


Sponsors and Collaborators
Alcon Research
Investigators
Study Director: Sr. Clinical Manager, GCRA Surgical Alcon, a Novartis Company
  More Information

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT01699087     History of Changes
Other Study ID Numbers: C-10-084
First Submitted: September 27, 2012
First Posted: October 3, 2012
Results First Submitted: January 3, 2017
Results First Posted: April 10, 2017
Last Update Posted: April 10, 2017
Last Verified: February 2017

Keywords provided by Alcon Research:
PRK
myopia
astigmatism

Additional relevant MeSH terms:
Myopia
Astigmatism
Refractive Errors
Eye Diseases